{
  "trial_id": "NCT03976843",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "histologically proven prostate adenocarcinoma",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "prostate cancer with high risk features defined as Gleason 8 and higher OR PSA > 20 ng/mL OR clinical stage T3a (i.e. likely extraprostatic extension on MRI) or T3b",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "eligible for and planning to undergo radical prostatectomy and lymphadenectomy regardless of findings on 18F-DCFPyL PET/CT",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "age greater than or equal to 18 years",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "ECOG performance status <2",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "adequate organ and marrow function as defined below: Hemoglobin greater than or equal to 9 g/dL, leukocytes greater than or equal to 3,000/mcL, platelets greater than or equal to 100,000/mcL, total bilirubin <2 X normal institutional limits, AST(SGOT)/ALT(SGPT) less than or equal to 3 X normal institutional limits, creatinine <2 X normal institutional limits, eGFR greater than or equal to 50 mL/min/1.73 m2 for patients with creatinine levels above institutional normal",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "ability of subject to understand and the willingness to sign a written informed consent document",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "willingness and ability to undergo biopsy of radiotracer-avid lesion if feasible",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "willingness and ability to undergo multiparametric prostate MRI and 18F-DCFPyL PET/CT",
      "label": "met",
      "evidence": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "any investigational agents in the past 28 days prior to enrollment",
      "label": "not_met",
      "evidence": "quote"
    },
    {
      "criterion": "clinical stage T4 (tumor invades adjacent structures except seminal vesicles)",
      "label": "not_met",
      "evidence": "unknown"
    },
    {
      "criterion": "distant metastatic disease on conventional imaging studies (computed tomography of the abdomen and pelvis and 99mTc-methylene diphosphonate bone scan (bone scan))",
      "label": "not_met",
      "evidence": "quote"
    },
    {
      "criterion": "any prior hormone therapy used to treat prostate cancer, except limited androgen receptor antagonist therapy, defined as less than or equal to 3 days of treatment. The medication must be discontinued within 5 half-lives of the compound prior to study entry",
      "label": "not_met",
      "evidence": "quote"
    },
    {
      "criterion": "any prior therapy for prostate cancer with surgery, radiation, and/or chemotherapy",
      "label": "not_met",
      "evidence": "unknown"
    }
  ],
  "notes": "Patient is a 63-year-old man presenting to the Emergency Department with a history of acute urinary retention in the past 2 days. Abdominopelvic CT scan revealed a large prostate and a bladder filled with urine.",
  "_meta": {
    "topic_id": "60",
    "trial_id": "NCT03976843",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}